Biotek-snakken — April 2024
-
Vicore Pharma også på vej op af hullet fra bunden omkring kurs 13 til nu 18,4….er de små biotek selskaber generelt blevet attraktive igen efter en total udbombning?
-
Biotekselskab sigter mod milliardstor børsnotering https://borsen.dk/nyheder/virksomheder/dansk-biotekselskab-aabner-for-milliardstor-borsnotering?b_source=borsen&b_medium=row_0&b_campaign=news_2
-
"Comments
Calliditas delivered strong Q4 results and with Tarpeyo’s full FDA
approval granted in December 2023, we have decided to update
our estimates according to the current trajectory. With the sales
unleashing full approval(s) and weak competition, ... -
... we remain
optimistic and expect the first (organically) profitable quarter to be
Q3 2024 – if the company continues to step up its commercial
efforts. With the updated forecasts, we have reached a fair value
of SEK 177 but have decided to maintain our target price of SEK
161 due to low growth expected for Q1 2024."
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind